Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
← catalyst calendarSponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
603actual
Sites
227
Countries
Australia, Austria, Belgium +17
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-11-17 | actual | When the study began enrolling |
| Primary completion | 2023-11-29 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2021-10-22 | actual | When this record first appeared on the registry |
| Results posted | 2025-01-14 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-05-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer
Interventions
- Biological: Sacituzumab Govitecan-hziy (SG) — also filed as IMMU-132, GS-0132
- Drug: Docetaxel
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS)
measured Up to 24.4 months
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2022-12-22 · 1.5 MB · Prot_000.pdf
Statistical Analysis Planposted 2023-07-12 · 1.5 MB · SAP_001.pdf
Publications
- PMID 38843511 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed